The Ivermectin Market growth is primarily driven by rising global incidence of parasitic infections and increased use of preventive healthcare treatments. Government health programs and non-profit initiatives are also contributing to wider drug accessibility. Additionally, improved awareness in rural and underserved regions is significantly boosting consumption levels.

Technological improvements in drug formulation and manufacturing efficiency are further supporting market expansion. Pharmaceutical companies are investing in research and production optimization to enhance drug effectiveness and reduce costs. These combined factors are creating a stable and expanding growth environment for the industry.

FAQ

Q1: What is the main growth driver?
A1: Increasing parasitic infections worldwide.

Q2: How do governments support growth?
A2: Through public health programs and drug access.

Q3: Are companies investing in R&D?
A3: Yes, for improved formulations.